

PHILIPS

January 25, 2024

To Philips Respironics US Customers:

We are reaching out to inform you of strategic choices we've made to the Philips Respironics Sleep & Respiratory Care portfolio in the US to focus on programs that are best suited to changing market dynamics and will most effectively serve patients and customers in the future.

Effective immediately for customers in the US, including US territories, we have made the decision to discontinue the manufacture and sale of hospital ventilation products; certain home ventilation products (including Philips Respironics Trilogy Evo); portable and stationary oxygen concentrators; and sleep diagnostic products. Philips Respironics will continue to support service and provide service parts and accessories for discontinued products through the 'end of service' date, or as long as they are available. This has no effect on consumables and accessories, including masks. To see the list of impacted products and their 'end of service' date, please visit philips.com/src-portfolio-update.

★ May still continue using ★

Importantly, these changes to our portfolio do not affect our commitment to the remediation of devices included in the June 2021 recall of certain CPAP, BiPAP and mechanical ventilator devices.

Our business outside of the US

Outside of the US, we will continue sales and support of our current sleep and respiratory products.

What's next

You will be contacted directly regarding any order cancellations. We understand the magnitude of this announcement and the impact it has on you, our valued partners, and the patients you serve. Philips remains committed to the Sleep & Respiratory Care business. While these changes are difficult, they are necessary to help us refocus our portfolio on solutions that will most effectively serve patients and customers in the future.

Separately, Philips Respironics remains in ongoing discussions with the US Department of Justice (DOJ), representing the US Food and Drug Administration (FDA), regarding the terms of the proposed consent decree and will provide updates as they become available.

Please reach out to Customer Service with any questions, or visit philips.com/src-portfolio-update.

Thank you for your continued support as we work to regain your trust.

Sincerely,

Rahul Gundala
Business Category Leader, Patient Interface & Software
Philips Respironics

Sam Talya
Business Category Leader, Therapy Platforms
Philips Respironics

